RIGL Q3 2020 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$517M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M-11.8% YoY

Gross Profit

$18M99.2% margin

Operating Income

-$14M-74.9% margin

Net Income

-$14M-77.1% margin

EPS (Diluted)

$-0.84

QoQ Revenue Growth

+14.8%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$20M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$123M

Total Liabilities

$72M

Stockholders' Equity

$51M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$21M	-11.8%
Gross Profit	$18M	$21M	-11.2%
Operating Income	-$14M	-$12M	-14.5%
Net Income	-$14M	-$11M	-23.4%

Revenue Segments

Gross Product

$20M55%

Product

$16M44%

Contract Revenues From Collaborations

$2M6%

License

$2M6%

Discounts And Allowances

-$4M-11%